SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Versant Venture Management, LLC

CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877

Reported Value
$242M
Q3 2021
Positions
11
Filings on Record
30
2019–present window
Filed
Nov 12, 2021
original filing

Summary

Versant Venture Management, LLC reported $242M in U.S.-listed holdings across 11 positions for Q3 2021.

The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 23.1% of reported value.

The book was largely unchanged from Q2 2021.

Portfolio Metrics

Turnover
+1.7%
vs prior filed quarter
Top-10 Concentration
+99.8%
share of reported value
Largest Position
+23.1%
Crispr Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $202.0BQ4 ’18Q1 ’19: $303.6BQ2 ’19: $343.2BQ3 ’19: $258.5BQ4 ’19: $331.8BQ4 ’19Q1 ’20: $364.6BQ2 ’20: $696.1BQ4 ’20: $963MQ1 ’21: $513MQ1 ’21Q2 ’21: $302MQ3 ’21: $242MQ4 ’21: $187MQ1 ’22: $100MQ1 ’22Q2 ’22: $65MQ3 ’22: $59MQ4 ’22: $48MQ1 ’23: $48MQ1 ’23Q2 ’23: $84MQ3 ’23: $188MQ4 ’23: $389MQ1 ’24: $103MQ1 ’24Q2 ’24: $77MQ3 ’24: $64MQ4 ’24: $87MQ1 ’25: $60MQ1 ’25Q2 ’25: $82MQ3 ’25: $212MQ4 ’25: $151MQ1 ’26: $141MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Other: 63.7%Common Stock: 36.3%
  • Other · 63.7% · $154M
  • Common Stock · 36.3% · $88M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
2JQGritstone Oncology, Inc.TRIMMED−444.7K4.01M+$3M$43M
CRISPR Therapeutics AGHELD−10.0K498.6K−$27M$56M
Passage Bio, Inc.HELD+04.96M−$16M$49M
Aligos Therapeutics, Inc.HELD+02.32M−$11M$36M
ADVMCHFAdverum Biotechnologies, Inc.HELD+05.07M−$7M$11M
Flexion Therapeutics, Inc.HELD+01.00M−$2M$6M
CRNXCrinetics Pharmaceuticals, Inc.HELD+0820.7K+$2M$17M
AKROAkero Therapeutics, Inc.HELD+0617.7K−$2M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

11 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CRISPR Therapeutics AGCommon Shares23.11%$56M498.6K
2Passage Bio, Inc.Common Stock20.45%$49M4.96M
32JQGritstone Oncology, Inc.history →Common Stock17.91%$43M4.01M
4Aligos Therapeutics, Inc.Common Stock14.90%$36M2.32M
5CRNXCrinetics Pharmaceuticals, Inc.history →Common Stock7.15%$17M820.7K
6AKROAkero Therapeutics, Inc.history →Common Stock5.72%$14M617.7K
7ADVMCHFAdverum Biotechnologies, Inc.history →Common Stock4.55%$11M5.07M
8Aprea Therapeutics, IncCommon Stock2.67%$6M1.26M
9Flexion Therapeutics, Inc.Common Stock2.53%$6M1.00M
10CymaBay Therapeutics, Inc.Common Stock0.82%$2M543.8K
11CLVSEURClovis Oncology, Inc.Common Stock0.19%$454,000101.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$141M8May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$151M7Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$212M9Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$82M8Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$60M7May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$87M7Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$64M6Nov 8, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M8Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$103M7May 3, 202413F-HRchanges · EDGAR ↗
Q4 2023$389M7Feb 8, 202413F-HRchanges · EDGAR ↗
Q3 2023$188M8Nov 3, 202313F-HRchanges · EDGAR ↗
Q2 2023$84M8Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$48M7May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$48M7Feb 9, 202313F-HRchanges · EDGAR ↗
Q3 2022$59M8Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$65M8Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$100M10May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$187M10Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$242M11Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$302M11Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$513M11May 7, 202113F-HRchanges · EDGAR ↗
Q4 2020$963M12Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020Under review11Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$696.1B12Jul 20, 202013F-HRchanges · EDGAR ↗
Q1 2020$364.6B9Apr 28, 202013F-HRchanges · EDGAR ↗
Q4 2019$331.8B7Jan 21, 202013F-HRchanges · EDGAR ↗
Q3 2019$258.5B8Oct 8, 201913F-HRchanges · EDGAR ↗
Q2 2019$343.2B9Jul 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$303.6B9Apr 5, 201913F-HRchanges · EDGAR ↗
Q4 2018$202.0B10Jan 22, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.